基于人类免疫缺陷病毒（HIV）状态和疫苗类型的新冠病毒（SARS-CoV-2）mRNA疫苗接种后免疫球蛋白G（IgG）浓度及替代病毒中和试验反应的差异：一项配对病例对照观察性研究
Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study.
作者信息
Spinelli Matthew A, Peluso Michael J, Lynch Kara L, Yun Cassandra, Glidden David V, Henrich Timothy J, Deeks Steven G, Gandhi Monica
机构信息
Division of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.
Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
出版信息
Clin Infect Dis. 2022 Aug 24;75(1):e916-e919. doi: 10.1093/cid/ciab1009.
Following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination, people living with human immunodeficiency virus (HIV, PLWH) had lower surrogate virus neutralization test response (P = .03) and a trend toward lower immunoglobulin G (IgG) response (P = .08), particularly among those with lower CD4+ T-cell counts and who received the BNT162b2 vaccine. Study of the impact of supplemental vaccine doses among PLWH is needed.
在接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗后，人类免疫缺陷病毒（HIV）感染者（PLWH）的替代病毒中和试验反应较低（P = 0.03），免疫球蛋白G（IgG）反应有降低趋势（P = 0.08），尤其是在CD4+T细胞计数较低且接种BNT162b2疫苗的人群中。需要研究补充疫苗剂量对PLWH的影响。
Zotero 插件